Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases ; volume:22 ; number:1 ; day:2 ; month:1 ; year:2024 ; pages:1-12 ; date:12.2024
Pediatric rheumatology ; 22, Heft 1 (2.1.2024), 1-12, 12.2024
- Creator
-
Welzel, Tatjana
Golhen, Klervi
Atkinson, Andrew
Gotta, Verena
Ternant, David
Kuemmerle-Deschner, Jasmin B.
Michler, Christine
Koch, Gilbert
den Anker, Johannes N. van
Pfister, Marc
Woerner, Andreas
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12969-023-00930-8
- URN
-
urn:nbn:de:101:1-2024031810060017428147
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Welzel, Tatjana
- Golhen, Klervi
- Atkinson, Andrew
- Gotta, Verena
- Ternant, David
- Kuemmerle-Deschner, Jasmin B.
- Michler, Christine
- Koch, Gilbert
- den Anker, Johannes N. van
- Pfister, Marc
- Woerner, Andreas
- SpringerLink (Online service)
Other Objects (12)
Macrophage activation syndrome (MAS) in different pediatric rheumatic disease
Reducing fatigue in pediatric rheumatic conditions: a systematic review
Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial
Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series
The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Pediatric rheumatic disease patients: time to extend the age limit of adolescence?
AVT02: An Adalimumab Biosimilar
Rheumatic disease
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Macrophage activation syndrome (MAS) in different pediatric rheumatic disease
Reducing fatigue in pediatric rheumatic conditions: a systematic review
Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial
Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series
The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Pediatric rheumatic disease patients: time to extend the age limit of adolescence?
AVT02: An Adalimumab Biosimilar
Rheumatic disease
Demonstration of Physicochemical and Functional Similarity of Biosimilar Adalimumab-aqvh to Adalimumab
Macrophage activation syndrome (MAS) in different pediatric rheumatic disease
Reducing fatigue in pediatric rheumatic conditions: a systematic review
Cost-Effectiveness of Therapeutic Drug Monitoring-Guided Adalimumab Therapy in Rheumatic Diseases: A Prospective, Pragmatic Trial
Adalimumab to treat noninfectious pediatric chronic anterior uveitis: a case series
Humira (Adalimumab) : Adalimumab in der Therapie der Psoriasis
Non-criteria antiphospholipid antibodies and pediatric rheumatic disease: a case series
The Non-medical Switch from Reference Adalimumab to Biosimilar Adalimumab is Highly Successful in a Large Cohort of Patients with Stable Inflammatory Rheumatic Joint Diseases: A Real-Life Observational Study
Adalimumab and anti-adalimumab LISA-TRACKER immunoassays performance criteria for therapeutic drug monitoring of adalimumab-amgen biosimilar (ABP501)
Pediatric rheumatic disease patients: time to extend the age limit of adolescence?
AVT02: An Adalimumab Biosimilar
Rheumatic disease